SCHEMBL2270832

SCHEMBL2270832

[SiH3]C(=C(Cl)c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43
DAO P14920 1/20 0.43
NAPRT Q6XQN6 1/20 0.43
ALDH1A1 P00352 4/20 0.43
HIF1A Q16665 2/20 0.43
CES1 P23141 5/20 0.38
CES2 O00748 4/20 0.38
SRD5A2 P31213 1/20 0.37
ESR1 P03372 1/20 0.36
MAPK1 P28482 2/20 0.36
TRPA1 O75762 1/20 0.36
GSK3B P49841 1/20 0.36
F2 P00734 2/20 0.35
CYP3A4 P08684 2/20 0.35
MAPT P10636 2/20 0.35
BLM P54132 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
F10 P00742 1/20 0.35
F12 P00748 1/20 0.35
F7 P08709 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2103298 0.81 TSHR (0.46) TSHRDAONAPRTALDH1A1HIF1A
SCHEMBL1062320 0.81 CES1 (0.39) TSHRDAONAPRTALDH1A1HIF1A
SCHEMBL3940728 0.80 TSHR (0.56) TSHRDAONAPRTALDH1A1HIF1A
SCHEMBL3940726 0.80 TSHR (0.56) TSHRDAONAPRTALDH1A1HIF1A
SCHEMBL15302785 0.77 CES2 (0.41) TSHRDAONAPRTALDH1A1HIF1A
SCHEMBL7875628 0.75 TSHR (0.50) TSHRDAONAPRTALDH1A1HIF1A
SCHEMBL59763 0.75 TSHR (0.50) TSHRDAONAPRTALDH1A1HIF1A
SCHEMBL18294893 0.72 ESR1 (0.50) TSHRDAONAPRTALDH1A1HIF1A
SCHEMBL724164 0.72 CES1 (0.41) TSHRDAONAPRTALDH1A1CES1
SCHEMBL15301913 0.72 ATM (0.43) ALDH1A1HIF1ACES1CES2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466850-B2 Method for producing peptide compound NISSAN CHEMICAL CORPORATION (JP) 2025-11-11 US disclosed
EP-4023661-B1 METHOD FOR PRODUCING PEPTIDE COMPOUND NISSAN CHEMICAL CORP (JP) 2024-09-04 EP disclosed
CN-114206901-B Process for producing peptide compound 日产化学株式会社 2024-02-20 CN disclosed
US-20220306682-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND NISSAN CHEMICAL CORPORATION (JP) 2022-09-29 US disclosed
EP-4023661-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND Nissan Chemical Corporation (JP) 2022-07-06 EP disclosed
CN-114206901-A Method for producing peptide compound 日产化学株式会社 2022-03-18 CN disclosed
CN-109415447-B Silane-mediated enhancement of rubber storage stability 盛禧奥欧洲有限责任公司 2021-06-15 CN disclosed
WO-2021039901-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND 日産化学株式会社 2021-03-04 WO disclosed
US-10858377-B2 Multivinylaminosilanes as branching agents for functionalized elastomeric polymers TRINSEO EUROPE GMBH (CH) 2020-12-08 US disclosed
CN-107406467-B Polyvinylaminosilanes as branching agents for functionalized elastomeric polymers 盛禧奥欧洲有限责任公司 2020-11-10 CN disclosed
US-20180030070-A1 Multivinylaminosilanes as Branching Agents for Functionalized Elastomeric Polymers TRINSEO EUROPE GMBH (CH) 2018-02-01 US disclosed
WO-2017216344-A1 SILANE-MEDIATED ENHANCEMENT OF RUBBER STORAGE STABILITY TRINSEO EUROPE GMBH (CH) 2017-12-21 WO disclosed
EP-3257869-A1 SILANE-MEDIATED ENHANCEMENT OF RUBBER STORAGE STABILITY Trinseo Europe GmbH (CH) 2017-12-20 EP disclosed
WO-2016131590-A1 MULTIVINYLAMINOSILANES AS BRANCHING AGENTS FOR FUNCTIONALIZED ELASTOMERIC POLYMERS TRINSEO EUROPE GMBH (CH) 2016-08-25 WO disclosed
EP-3059240-A1 Multivinylaminosilanes as branching agents for functionalized elastomeric polymers Trinseo Europe GmbH (CH) 2016-08-24 EP disclosed
US-8871890-B2 Curable resin composition and cured article DAICEL CORPORATION (JP) 2014-10-28 US disclosed
EP-2636706-A1 CURABLE RESIN COMPOSITION AND CURED ARTICLE Daicel Corporation (JP) 2013-09-11 EP disclosed
US-20130131265-A1 CURABLE RESIN COMPOSITION AND CURED ARTICLE DAICEL CORPORATION (JP) 2013-05-23 US disclosed
US-8404584-B2 Method of manufacturing semiconductor device FUJITSU LIMITED (JP) 2013-03-26 US disclosed
US-20110207319-A1 METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE FUJITSU LIMITED (JP) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030070-A1 Multivinylaminosilanes as Branching Agents for Functionalized Elastomeric Polymers GMNN, GNE, MSN TSHR 2520/4885DAO 1066/4885NAPRT 2635/4885
US-12466850-B2 Method for producing peptide compound VIP, NGLY1, NPR1 TSHR 288/4885DAO 512/4885NAPRT 4130/4885
US-20220306682-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND VIP, NGLY1, NPR1 TSHR 288/4885DAO 512/4885NAPRT 4130/4885
US-10858377-B2 Multivinylaminosilanes as branching agents for functionalized elastomeric polymers GMNN, GNE, MSN TSHR 2520/4885DAO 1066/4885NAPRT 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.